# Supplementary TABLES

Supplementary Table 1. Summary of ADC Pharmacokinetic Parameters

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study/ADC | Dose (mg/kg) | Cmax 1st Dose(µg/mL) | Cmax 4th Dose (µg/mL) | AUC 0-21 1st Dose (day\*µg/mL) | T1/21st Dose(days) |
| 2009002/AGS-16M8F(Hyb) | 0.6 | 11.0 ± 1.96 | 11.0 ± 2.14 | 59.7 ± 19.8  | 5.67 (3.70-6.71) |
| 1.2 | 26.8 ± 6.27 | 18.1 | 134 ± 30.4 | 5.12 (3.50-5.53) |
| 1.8 | 39.6 ± 6.47 | 44.8 ± 13.5 | 287 ± 73.8 | 9.69 (6.32-12.6) |
| 2.7 | 51.8 ± 9.18 | 60.4 | 325 ± 94.9 | 5.97 (5.18-6.07) |
| 3.6 | 65.5 ± 8.74 | (57.0) | 430 ± 96.3 | 6.32 (5.46-8.22) |
| 4.8 | 113 ± 26.4 | 92.1 | 824 ± 113 | 9.58 (6.86-11.9) |
| AGS-16C3F-12-2/AGS-16C3F(CHO) | 1.8 | 47.4 ± 21.2 | 39.8 ± 7.68 | 227 ± 99.2 | 6.86 (2.67-9.16) |
| 2.7 | 57.2 ± 15.7 | 51.8 ± 19.6 | 392 ± 110 | 9.00 (6.66-13.2) |
| 3.6 | 109 ± 32.5  | - | 535 ± 215 | 8.50 (6.33-11.6) |
| 4.8 | 128 | - | (657)  |  (4.05, 8.70) |
| Data represented as mean ± SD except T1/2 which is reported as median (range). Median and SD not calculated when n≤2. Data reported in parentheses when n=1; Cmax was reported after the 1st and the 4th dose.T1/2 and AUC0-7 were estimated for the first dose only.  |

Supplementary Table 2. Summary of Cys-mcMMAF Pharmacokinetic Parameters

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study/ADC | Dose (mg/kg) | Cmax1st Dose(ng/mL) | Cmax4th Dose (ng/mL) | AUC 0-7 1st Dose (day\*ng/mL) | Tmax1st Dose(days) | T1/21st Dose(days) |
| 2009002/AGS-16M8F(Hyb) | 0.6 | 1.59 ± 0.512 | 1.25 ± 0.182 | - | 0.233 (0.196-0.333) | 1.55 (0.971-2.31) |
| 1.2 | 3.73 ± 0.899 | 2.71 | 6.55 | 0.208 (0.208-0.326) | 3.88 (2.59-5.17) |
| 1.8 | 5.02 ± 1.40 | 3.44 ± 0.0964 | 10.4 ± 3.22  | 0.208 (0.208-0.333) | 11.2 (7.58-13.9) |
| 2.7 | 14.0 ± 8.41 | 8.53 ± 3.21 | 24.3 ± 14.0 | 0.208 (0.198-0.333) | 4.15 (3.28-5.59) |
| 3.6 | 11.8 ± 1.36 | (16.8) | 16.0 ± 3.71 | 0.208 (0.124-0.208) | 2.91 (2.81-3.43) |
| 4.8 | 9.72 ± 6.38 | 10.1 | 19.1 ± 13.2 | 0.208 (0.163-0.219) | 4.81 (2.02-6.05) |
| AGS-16C3F-12-2/AGS-16C3F(CHO) | 1.8 | 4.58 ± 2.47 | 4.27 ± 1.47 | 7.72 ± 1.31 | 0.208 (0.126-0.330) | 3.35 (2.81-4.94) |
| 2.7 | 10.0 ± 3.72 | 4.74 ± 1.72 | 9.55 ± 2.62 | 0.209 (0.126-0.323) | 3.82 (3.30-5.70) |
| 3.6 | 13.0 ± 4.70 | - | 12.4 ± 3.17 | 0.208 (0.205-0.214) | 4.14 (3.29-4.67) |
| 4.8 | 16.7 | - | 21.9 | (0.199, 0.212) | (5.19) |
| Data represented as mean ± SD except T1/2 and Tmax which are reported as median (range). Median and SD not calculated when n≤2. Data reported in parentheses when n=1; Cmax was reported after the 1st and the 4th dose. Tmax and AUC0-7 were estimated for the first dose only. |

Supplementary Table 3. Summary of TAb Pharmacokinetic Parameters

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study/ADC | Dose (mg/kg) | Cmax 1st Dose(µg/mL) | Cmax 4th Dose (µg/mL) | AUC 0-21 1st Dose (day\*µg/mL) | T1/21st Dose(days) |
| 2009002/AGS-16M8F(Hyb) | 0.6 | 14.5 ± 1.26 | 15.5 ± 2.15 | 86.2 ± 18.7 | 6.70 (4.05-7.14) |
| 1.2 | 30.4 ± 7.26 | 23.3 | 177 ± 37.5 | 5.27 (3.72-7.33) |
| 1.8 | 49.3 ± 11.6 | 57.0 ± 12.5 | 397 ± 148 | 13.9 (7.96-15.5) |
| 2.7 | 63.8 ± 9.70 | 78.3 | 467 ± 127 | 6.86 (6.67-7.90) |
| 3.6 | 79.8 ± 8.07 | (65.3) | 590 ± 101 | 7.11 (5.71-10.2) |
| 4.8 | 127 ± 38.5 | 160 | 1070 ± 167 | 11.3 (4.07-12.8) |
| AGS-16C3F-12-2/AGS-16C3F(CHO) | 1.8 | 53.4 ± 18.1 | 47.7 ± 10.9 | 280 ± 72.9 | 8.29 (4.01-14.2) |
| 2.7 | 72.6 ± 14.3 | 63.3 ± 19.9 | 579 ± 278 | 8.82 (5.77-15.7) |
| 3.6 | 204 ± 174  | - | 755 ± 381 | 10.0 (7.71-15.5) |
| 4.8 | 149 | - | (907)  |  (6.79, 12.5) |
| Data represented as mean ± SD except T1/2 which is reported as median (range). Median and SD not calculated when n≤2. Data reported in parentheses when n=1; Cmax was reported after the 1st and the 4th dose.T1/2 and AUC0-7 were estimated for the first dose only. |

Supplementary Table 4. Pharmacokinetic properties of AGS-16M8F and AGS-16C3F

|  |  |  |
| --- | --- | --- |
|  | **AGS-16M8F(Hyb)****Median T1/2 (days)** | **AGS-16C3F(CHO)** **Median T1/2 (days)** |
| ADC  | 6.32 (3.50 – 12.6, n=25) | 7.60 (2.67 – 13.2 days, n=31) |
| Total Antibody (TAb)  | 7.13 (3.72 – 15.5, n=26) | 8.82 (4.01 – 15.7 days, n=31) |
| Cys-mcMMAF | 4.18 (0.97 – 13.9, n=22) | 4.02 (2.81 – 5.70 days; n=24) |

Supplementary Table 5. Summary of immunogenicity evaluation

|  |  |  |
| --- | --- | --- |
|  | **AGS-16M8F(Hyb)** **(N=26)** | **AGS-16C3F(CHO)** **(N=32)** |
| Subjects with baseline and at least 1 post baseline sample | 20 (77%) | 28 (87.5%) |
| Result | All negative for ADA | All negative for ADA |

Supplementary Table 6. Summary of IHC analysis (H-score)

|  |  |  |
| --- | --- | --- |
|   | **H-score** |   |
|   | **201-300** | **101-200** | **1-100** | **0** | **Total**  |
|   | **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** | **%** | **Number** |
| **Clear cell** | 21 | **78** | 4 | **15** | 1 | 4 | 1 | 4 | **27** |
| **Papillary cell** | 4 | **18** | 5 | **23** | 8 | 36 | 5 | 23 | **22** |
| **Other\*** | 2 | **15** | 1 | **8** | 4 | 31 | 6 | 46 | **13** |
| \*includes 12 unclassified, one chromophobe carcinoma |  |  |